



COPY OF PAPERS
ORIGINALLY FILED

644/1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Llinas-Brunet, M. et al

Appln. No. 09/368,670

Group Art Unit: 1653

Filed: 08/05/1999

Examiner: D. Lukton

For: Hepatitis C Inhibitor Peptides

Atty. Docket No. 13/063-2-C2

Commissioner For Patents
Washington, D.C. 20231

RECEIVED

MAR - 5 2002

TECH CENTER 1600/2900

STATEMENT UNDER 37 CFR § 1.821(a)

Sir:

In response to the Communication dated February 6, 2002, setting a one month period for response, a new computer readable form (CRF) Sequence Listing is submitted herewith.

I hereby certify that:

The new computer readable form (CRF) Sequence Listing submitted herewith is identical to the paper Sequence Listing submitted on November 14, 2001.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on February 12, 2002

By: Philip I. Datlow
Reg. No. 41,482